Roeben, Benjamin http://orcid.org/0000-0002-4905-8698
Liepelt-Scarfone, Inga http://orcid.org/0000-0002-0875-892X
Lerche, Stefanie http://orcid.org/0000-0002-5508-004X
Zimmermann, Milan http://orcid.org/0000-0001-7066-7749
Wurster, Isabel
Sünkel, Ulrike http://orcid.org/0000-0002-5348-3996
Schulte, Claudia
Deuschle, Christian
Eschweiler, Gerhard W.
Maetzler, Walter http://orcid.org/0000-0002-5945-4694
Gasser, Thomas http://orcid.org/0000-0002-1069-1146
Berg, Daniela
Brockmann, Kathrin http://orcid.org/0000-0002-7515-8596
Article History
Received: 2 November 2023
Accepted: 8 April 2024
First Online: 22 April 2024
Competing interests
: B.R. was supported by the Clinician Scientist program of the Medical Faculty of the University of Tübingen (grant #478-0-0). I.L.S. has received grants from Janssen Research and Development, a division of Janssen Pharmaceutica N.V. and grants from the Michael J. Fox Foundation; grants from European Commission, H2020-TWINN-2015, International Parkinson Fonds (Deutschland) GmbH (IPD), Novartis and German Ministry for Education and Research (BMBF). S.L. has nothing to disclose. M.Z. was supported by the Clinician Scientist program of the Medical Faculty of the University of Tübingen (grant #481-0-0). I.W. received funding from the Michael J. Fox Foundation in form of the Edmond J. Safra Fellowship in Movement Disorders. C.S. has nothing to report. C.D. has nothing to report. G.W.E. has received grants from the German Federal Ministry of Education of Research (BMBF), German Research Council (DFG), German Innovationsfonds but not from industrial partners. W.M. receives or received funding from the European Union, the German Federal Ministry of Education of Research, German Research Council, Michael J. Fox Foundation, Robert Bosch Foundation, Neuroalliance, Lundbeck, Sivantos and Janssen. He received speaker honoraria from Abbvie, Bayer, BIAL, GlaxoSmithKline, Heel, Licher MT, Pfizer, Takeda and UCB, was invited to Advisory Boards/Consultancies of Abbvie, Aptar Digital Health, Atheneum, Biogen, Kyowa Kirin, Lundbeck and Market Access & Pricing Strategy GmbH, is an advisory board member of the Critical Path for Parkinson’s Consortium, and an editorial board member of Geriatric Care. He serves as the co-chair of the MDS Technology Working Group. T.G. serves as associate editor at Journal of Parkinson’s disease; holds a patent re: KASPP (LRRK2) Gene, its Production and Use for the Detection and Treatment of Neurodegenerative Diseases; serves as a consultant for Cephalon, Inc. and Merck Serono; serves on speaker’s bureaus of Novartis, Merck Serono, SCHWARZ PHARMA, Boehringer Ingelheim, and Valeant Pharmaceuticals International; and receives research support from Novartis, the European Union, BMBF (the Federal Ministry of Education and Research), and Helmholtz Association. D.B. has served on scientific advisory boards for UCB/ SCHWARZ PHARMA, Lundbeck, Biogen and BIAL.; has received funding for travel or speaker honoraria from Lundbeck Inc., Novartis, UCB/ SCHWARZ PHARMA, Merck Serono, Biogen, Zambon, AbbVie, and BIALLtd.; and has received research support from Janssen, Teva Pharmaceutical Industries Ltd., Solvay Pharmaceuticals, Inc./Abbott, Boehringer, UCB, Michael J Fox Foundation, BMBF, dPV (German Parkinson’s disease association), Neuroallianz, DZNE,Center of Integrative Neurosciences and the Damp Foundation. K.B. has received research grants from the University of Tuebingen (Clinician Scientist), the German Society of Parkinson’s disease (dpv), the Michael J. Fox Foundation (MJFF), the German Centre for Neurodegenerative Diseases (DZNE, MIGAP) and the German Federal Ministry of Education and Research (BMBF) in the frame of ERACoSysMed2 (FKZ 031L0137B). She received Speaker honoraria from Abbvie, Lundbeck, UCB and Zambon. She serves as consultant for Roche.